TherapeuticsMD, Inc. (NASDAQ:TXMD) shares traded down 6.4% on Tuesday . The stock traded as low as $6.08 and last traded at $6.17. 3,289,261 shares changed hands during mid-day trading, an increase of 13% from the average session volume of 2,918,448 shares. The stock had previously closed at $6.59.
Several research analysts have weighed in on the company. BidaskClub lowered TherapeuticsMD from a “hold” rating to a “sell” rating in a research report on Wednesday, September 27th. Jefferies Group reissued a “buy” rating and set a $15.00 price objective on shares of TherapeuticsMD in a report on Tuesday, September 26th. Deutsche Bank set a $10.00 price objective on TherapeuticsMD and gave the company a “buy” rating in a report on Tuesday, August 22nd. Oppenheimer reissued an “outperform” rating and set a $10.00 price objective on shares of TherapeuticsMD in a report on Thursday, August 31st. Finally, Stifel Nicolaus reissued a “buy” rating and set a $20.00 price objective on shares of TherapeuticsMD in a report on Monday, August 21st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $15.00.
TherapeuticsMD (NASDAQ:TXMD) last announced its earnings results on Monday, November 6th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.03. TherapeuticsMD had a negative return on equity of 65.16% and a negative net margin of 457.00%. The firm had revenue of $4.42 million during the quarter, compared to the consensus estimate of $5.36 million. During the same quarter in the prior year, the company earned ($0.13) EPS. The firm’s revenue for the quarter was down 19.7% compared to the same quarter last year. analysts expect that TherapeuticsMD, Inc. will post -0.37 EPS for the current year.
A number of large investors have recently made changes to their positions in TXMD. JPMorgan Chase & Co. lifted its position in shares of TherapeuticsMD by 40.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 22,027,855 shares of the company’s stock worth $112,783,000 after acquiring an additional 6,340,346 shares during the period. Bank of New York Mellon Corp lifted its position in shares of TherapeuticsMD by 13.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 25,877,864 shares of the company’s stock worth $136,894,000 after acquiring an additional 2,985,846 shares during the period. Stifel Financial Corp lifted its position in shares of TherapeuticsMD by 377.9% in the 2nd quarter. Stifel Financial Corp now owns 2,052,030 shares of the company’s stock worth $10,820,000 after acquiring an additional 1,622,668 shares during the period. Voya Investment Management LLC lifted its position in shares of TherapeuticsMD by 33.4% in the 2nd quarter. Voya Investment Management LLC now owns 2,959,107 shares of the company’s stock worth $15,595,000 after acquiring an additional 741,588 shares during the period. Finally, State Street Corp lifted its position in shares of TherapeuticsMD by 14.9% in the 2nd quarter. State Street Corp now owns 4,486,585 shares of the company’s stock worth $23,647,000 after acquiring an additional 583,094 shares during the period. Hedge funds and other institutional investors own 73.69% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “TherapeuticsMD (TXMD) Stock Price Down 6.4%” was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/12/19/therapeuticsmd-txmd-stock-price-down-6-4.html.
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
What are top analysts saying about TherapeuticsMD? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for TherapeuticsMD and related companies.